potent, oral heme-displacing IDO1 inhibitor
low predicted human dose (<10 mg QD)
from ALIS mass-based binding screen + SBDD
ACS Med. Chem. Lett., Jul. 15, 2020
Merck & Co., Boston, MA
“compound 2”
“compound 2” is a heme-displacing IDO1 inhibitor with a similar binding mode to BMS-986205 with a low projected human dose. A bis-amide hit was generated from a mass-spectrometry based binding…